

Voting Results of 2018 Annual General Meeting

LONDON, 17 May 2019 – Hikma Pharmaceuticals PLC (the “**Company**”) announces its Annual General Meeting (“**AGM**”), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 17 May 2019 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 were passed as ordinary resolutions and Resolutions 17 to 20 were passed as special resolutions.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 15 April 2019) is set out below. The number of Ordinary Shares in issue on 17 May 2019 was 242,013,996.

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
1. To receive the 2018 report and accounts	198,016,257	99.99	15,248	0.01	198,031,505	145,325
2. To approve a final dividend of 26 cents per share	198,172,485	100.00	437	0.00	198,172,922	3,909
3. To re-appoint PricewaterhouseCoopers LLP as auditors	198,168,429	100.00	2,171	0.00	198,170,600	6,231
4. To authorise the Audit Committee to determine the auditors’ remuneration	198,169,496	100.00	1,989	0.00	198,171,485	5,346
5. To re-elect Said Darwazah as a director	191,458,492	96.61	6,712,792	3.39	198,171,284	5,546
6. To re-elect Soggi Olafsson as a director	194,921,594	98.36	3,251,178	1.64	198,172,772	4,059
7. To re-elect Mazen Darwazah as a director	191,501,356	96.63	6,670,679	3.37	198,172,035	4,796
8. To re-elect Robert Pickering as a director	186,397,645	94.06	11,763,463	5.94	198,161,108	15,722
9. To re-elect Ali Al-Husry as a director	189,606,735	95.68	8,564,549	4.32	198,171,284	5,546
10. To re-elect Patrick Butler as a director	194,287,800	98.04	3,883,484	1.96	198,171,284	5,546
11. To re-elect Dr. Pamela Kirby as a director	182,139,906	91.91	16,032,128	8.09	198,172,034	4,796
12. To re-elect Dr. Jochen Gann as a director	194,395,430	98.09	3,775,854	1.91	198,171,284	5,546
13. To re-elect John Castellani as a director	195,035,397	98.42	3,135,888	1.58	198,171,285	5,546

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
14. To re-elect Nina Henderson as a director	194,490,204	98.14	3,681,830	1.86	198,172,034	4,796
15. To approve the remuneration report for the year ended 31 December 2018	190,476,075	96.12	7,695,409	3.88	198,171,484	5,346
16. Authority to allot shares	168,835,150	85.20	29,337,771	14.80	198,172,921	3,909
17. To dis-apply pre-emption rights for general purposes	198,116,024	99.97	56,161	0.03	198,172,185	4,646
18. To dis-apply pre-emption rights for an acquisition or other capital investment	195,242,802	98.52	2,929,382	1.48	198,172,184	4,646
19. To authorise the Company to purchase its own shares	197,396,007	99.66	682,740	0.34	198,078,747	98,083
20. To authorise the Company to hold general meetings on no less than 14 clear days' notice	187,234,093	94.48	10,936,803	5.52	198,170,896	5,785

Declaration of final dividend

The dividend of 26 cents per share will be paid on 22 May 2019 to shareholders on the register on 5 April 2019. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be \$1.2928 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to \$1.41.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs
Company Secretary

+44 20 7399 2670

Susan Ringdal
EVP, Strategic Planning and Global Affairs

+44 20 7399 2670

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide

them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

LEI: 549300BNS685UXH4JI75